Soleno Therapeutics closed at $52.26, up 32.31% after Neurocrine Biosciences offered $53 per share in an all-cash acquisition. The unsolicited buyout offer drove a large share-price move and creates near-term deal/ regulatory close risk that investors will monitor.
Soleno Therapeutics closed at $52.26, up 32.31% after Neurocrine Biosciences offered $53 per share in an all-cash acquisition. The unsolicited buyout offer drove a large share-price move and creates near-term deal/ regulatory close risk that investors will monitor.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
